Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Shares Outstanding (Weighted Average) (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Shares Outstanding (Weighted Average) readings, the most recent being $5.1 million for Q4 2023.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 1500.08% to $5.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $5.1 million, a 1500.08% increase, with the full-year FY2023 number at $5.1 million, up 1500.08% from a year prior.
  • Shares Outstanding (Weighted Average) hit $5.1 million in Q4 2023 for Elicio Therapeutics, up from $3.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $30.0 million in Q1 2022 to a low of $314572.0 in Q2 2022.
  • Median Shares Outstanding (Weighted Average) over the past 4 years was $14.5 million (2020), compared with a mean of $13.0 million.
  • The widest YoY moves for Shares Outstanding (Weighted Average): up 1500.08% in 2023, down 98.92% in 2023.
  • Elicio Therapeutics' Shares Outstanding (Weighted Average) stood at $14.8 million in 2020, then surged by 91.33% to $28.2 million in 2021, then crashed by 98.88% to $315998.0 in 2022, then soared by 1500.08% to $5.1 million in 2023.
  • The last three reported values for Shares Outstanding (Weighted Average) were $5.1 million (Q4 2023), $3.9 million (Q3 2023), and $2.9 million (Q2 2023) per Business Quant data.